Neuberger Berman Group’s VanEck Pharmaceutical ETF PPH Stock Holding History

Neuberger Berman Group’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,593	Closed	-$325K	–	2176
2025 Q3	$325K	Hold	3,593	–	–	﹤0.01%	1730
2025 Q2	$316K	Hold	3,593	–	–	﹤0.01%	1715
2025 Q1	$327K	Hold	3,593	–	–	﹤0.01%	1672
2024 Q4	$310K	Hold	3,593	–	–	﹤0.01%	1661
2024 Q3	$341K	Hold	3,593	–	–	﹤0.01%	1638
2024 Q2	$329K	Hold	3,593	–	–	﹤0.01%	1625
2024 Q1	$326K	Sell	3,593 -3,593	-50%	-$315K	﹤0.01%	1615
2023 Q4	$585K	Sell	7,186 -2,242	-24%	-$176K	﹤0.01%	1660
2023 Q3	$750K	Buy	9,428 +4,825	+105%	+$389K	﹤0.01%	1338
2023 Q2	$362K	Buy	4,603 +110	+2%	+$8.61K	﹤0.01%	1536
2023 Q1	$347K	Buy	4,493 +790	+21%	+$60.9K	﹤0.01%	1558
2022 Q4	$288K	Hold	3,703	–	–	﹤0.01%	1604
2022 Q3	$248K	Buy	+3,703	New	+$273K	﹤0.01%	1669

Other funds holding PPH

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BCIM

British Columbia Investment Management Victoria, British Columbia, Canada $16B AUM 37.57% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group's PPH Position: Q4 2025 in Review

Neuberger Berman Group sold out of VanEck Pharmaceutical ETF (PPH) in Q4 2025, closing a stake of 3,593 shares — an estimated $325K sold.

Neuberger Berman Group first reported a position in PPH in Q3 2022 and held it in 13 quarters. The position peaked at $750K in Q3 2023. 146 funds tracked by Wall St. Rank hold PPH as of Q4 2025.

Neuberger Berman Group reported no remaining VanEck Pharmaceutical ETF position as of Q4 2025 after selling out during the quarter.
Neuberger Berman Group sold 3,593 VanEck Pharmaceutical ETF shares in Q4 2025, an estimated $325K.
Neuberger Berman Group first reported a position in VanEck Pharmaceutical ETF in Q3 2022 and held it in 13 quarters.
Neuberger Berman Group's VanEck Pharmaceutical ETF position peaked at $750K in Q3 2023.
146 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q4 2025.

Based on Neuberger Berman Group's 13F filing for Q4 2025, filed 13 Feb 2026.